Modulators of sclerostin binding partners for treating bone-related disorders

Details for Australian Patent Application No. 2008209713 (hide)

Owner Novartis AG

Inventors Halleux, Christine; Lu, Chris Xiangyang; Hu, Shou-Ih; Kneissel, Michaela

Agent Davies Collison Cave

Pub. Number AU-B-2008209713

PCT Pub. Number WO2008/092894

Priority 60/887,956 02.02.07 US

Filing date 30 January 2008

Wipo publication date 7 August 2008

Acceptance publication date 19 January 2012

International Classifications

A61K 38/18 (2006.01) Medicinal preparations containing peptides - Growth factors

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 19/10 (2006.01) Drugs for skeletal disorders

Event Publications

30 July 2009 PCT application entered the National Phase

  PCT publication WO2008/092894 Priority application(s): WO2008/092894

19 January 2012 Application Accepted

  Published as AU-B-2008209713

17 May 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008209720-Polypeptides having phytase activty and polynucleotides encoding same

2008209701-Injection gateway